Subscribe
bayer-sign
15 October 2013Asia

Bayer takes another swipe at Nexavar compulsory licence

Bayer has appealed against the Indian Intellectual Property Appellate Board (IPAB)’s compulsory licence (CL) order that allows domestic generic maker Natco Pharma to market its own version of liver and kidney cancer drug Nexavar, this time at the Mumbai High Court.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Asia
Bayer’s compulsory licence appeal set to start in India
29 October 2013   A court appeal by Bayer against India’s first ever compulsory licence on its patented cancer drug will start today, October 29.
Big Pharma
India rejects Bayer plea over compulsory licence
4 March 2013   India’s patent authorities have dealt a blow to German pharma company Bayer by refusing to overturn an order forcing the company to license one of its patented drugs.


Editor's picks

UKIPO rejects Boehringer’s SPC for horse inhaler
Europe
UKIPO rejects Boehringer’s SPC for horse inhaler
8 July 2025

Editor's picks

Europe
UKIPO rejects Boehringer’s SPC for horse inhaler
8 July 2025
Americas
Bankruptcy judge approves $305m sale of genetics testing company
1 July 2025
Americas
A step too far? Why Stewart’s approach is dividing opinion
24 June 2025
Europe
Diverging in the detail: UPC local divisions and Court of Appeal take different paths
19 June 2025
Europe
UPC confirms permanent injunction against Curio in 10x tech dispute
17 June 2025
Americas
LSPN: In-house ‘chess game’ is the same, but the rules have changed
9 May 2025

More on this story

Asia
Bayer’s compulsory licence appeal set to start in India
29 October 2013   A court appeal by Bayer against India’s first ever compulsory licence on its patented cancer drug will start today, October 29.
Big Pharma
India rejects Bayer plea over compulsory licence
4 March 2013   India’s patent authorities have dealt a blow to German pharma company Bayer by refusing to overturn an order forcing the company to license one of its patented drugs.

More on this story

Asia
Bayer’s compulsory licence appeal set to start in India
29 October 2013   A court appeal by Bayer against India’s first ever compulsory licence on its patented cancer drug will start today, October 29.
Big Pharma
India rejects Bayer plea over compulsory licence
4 March 2013   India’s patent authorities have dealt a blow to German pharma company Bayer by refusing to overturn an order forcing the company to license one of its patented drugs.

More features

WATCH: The transparency tightrope—balancing innovation, regulation, and IP protection in a new era
Chicago firm Much Shelist adds partner with ‘entrepreneurial mindset’
Powell Gilbert launches Düsseldorf office with leading patent litigator
Startups toolkit: Why investors want more than patents
J&J fends off generic schizophrenia drug bids
Kilpatrick adds ‘seasoned litigator’ as trademark partner
WATCH: An update on EPO Board of Appeal strategy for 2025 and beyond
Startup challenges rival over brain monitoring tech at ITC